Revenue segments as reported by the company.

Premium and service revenues

Premium tax

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Depreciation

Amortization of acquired intangible assets

Premium tax expense

Health insurer fee expense

Impairment

Legal settlement

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Centene

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Centene exceeds earnings guidance, eyes growth in Marketplace products

Centene's Q4 2022 earnings call highlighted robust financial performance, successful execution of value-creation plans, and a focus on operational efficiency. While challenges in Medicare Advantage margins are anticipated, opportunities in the Marketplace business and cost-cutting initiatives offer avenues for growth. Strategic initiatives to address demographic shifts and enhance care relationships position Centene for future success.

Centene reports strong Q1 earnings, focuses on growth opportunities

Centene's Q1 performance reflects strength in financial results and a strategic outlook for future growth.
Despite challenges in Medicare profitability and Medicaid redeterminations, Centene remains focused on maximizing membership and maintaining high margins.
Opportunities in enhancing relationships, investing in infrastructure, and updating margin assumptions position Centene for long-term success.

Centene reports strong Q2 earnings, raises 2023 outlook amidst challenges

Centene's Q2 earnings call showcased robust financial performance, operational efficiencies, and strategic wins in Medicaid and Marketplace segments. While facing challenges in cost trends and Star ratings strategy, the company is well-positioned for growth through revenue expansion and value-creation initiatives. Opportunities for engagement with key stakeholders and successful outreach efforts present avenues for continued success.

Centene exceeds Q3 earnings expectations, eyes growth opportunities in 2024

Centene's Q3 2023 earnings call highlighted strong financial performance, progress in Medicaid redeterminations, and operational advancements. The company anticipates continued growth in adjusted EPS for 2023 and 2024, with a focus on margin expansion and operational efficiencies. Challenges include managing membership declines and addressing questions on business plans and cost implications.

Centene exceeds 2023 expectations, poised for growth in 2024

Centene's 2023 performance was strong, exceeding expectations and positioning the company for continued growth. Key initiatives in Medicaid, Medicare Advantage, and Marketplace are driving revenue growth and operational efficiency. Challenges in managing utilization trends and achieving target margins require ongoing attention.

Centene surpasses Q1 earnings expectations, eyes growth in Medicaid and Marketplace

Centene's Q1 performance exceeded expectations, showcasing strength in Medicaid and Marketplace segments.
While facing challenges in contract protests and operational clarity, the company's strategic focus on Medicare Advantage and growth opportunities remain key strengths.
With a robust financial outlook and ongoing initiatives for optimization, Centene is well-positioned for continued success in the healthcare market.
Investors can be optimistic about Centene's growth trajectory, supported by strong operational performance and strategic initiatives.

Centene reports robust Q2 earnings, eyes Medicaid rebound and Medicare growth

Centene's Q2 2024 earnings call highlighted strong performance, Medicaid challenges, and growth opportunities in Medicaid and Medicare markets. Leadership transitions and focus on program innovation are key areas of development for the company.

Centene surpasses Q3 earnings expectations, eyes growth amid challenges

Centene's Q3 performance exceeded expectations, driven by improvements in Medicaid and strong Medicare and Marketplace segments.
Despite challenges in Medicaid and competitive pressures, Centene remains confident in its future growth and operational enhancements.
The company's strategic focus on AI, margin expansion, and quality improvement positions it well for continued success and profitability.
Analyst inquiries and company responses highlighted key areas of focus and potential areas for improvement and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Horace Mann Educators

MSC Industrial Direct

Schweitzer-Mauduit

Vonage Hlds

The FPA Capital Fund (Trades, Portfolio), part of Los Angeles-based First Pacific Advisors (Trades, Portfolio), disclosed this week that its top three new buys during the fourth quarter of 2020 were in Horace Mann Educators Corp. (NYSE:HMN), Schweitzer-Mauduit International Inc. (NYSE:SWM) and MSC International Direct Co. Inc. (NYSE:MSM). Despite this, the fund's top sells, which included the closing of its Centene Corp. (NYSE:CNC) and Vonage Holdings Corp. (NASDAQ:VG) positions, outweigh its top buys.

FPA Capital Fund's Top Trades of the 4th Quarter

Cass Information Systems

City Hld

Clorox

51job

According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, the following five stocks have good financial strength and are trading near historical low price-book as of Wednesday: 51job Inc. (NASDAQ:JOBS), Centene Corp. (NYSE:CNC), Clorox Co. (NYSE:CLX), City Holding Co. (NASDAQ:CHCO) and Cass Information Systems Inc. (NASDAQ:CASS).

5 Historical Low Price-Book Companies for 2021

HealthEquity

With the transition to the Biden administration, the policy footing for the future of healthcare is veering once again. But no matter how you slice it, the future is about more flexible care with a greater diversity of end-market options, and the decreasing viability of a one-size-fits-all solution to managing policies.

Radar: Disruptors in Health Benefits Stocks (NYSE: CNC) (OTC US: LVGI) (NASDAQ: HQY)

Agilent Technologies

Baxter

Veeva Systems

Walgreens

According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.

5 Health Care Stocks Gurus Are Buying

When Centene Corp. (NYSE:CNC) announced the acquisition of Magellan Health Inc. (NASDAQ:MGLN) on Jan. 7, one line in the news release must have been music to investors' ears. The deal, Centene said, will create shareholder value through cost synergies and new growth opportunities.

Centene Shares Up 11% Just Days After Magellan Deal Announced

Rising costs and poor financial leverage make Centene (CNC) an unattractive stock now.

Here's Why You Should Steer Clear of Centene (CNC) Stock Now

Centene starts 2021 with a bolt-on deal, after a few large deals in recent years. Valuations look very modest, organic growth is solid, and earnings multiples look very reasonable.

Centene: Dealmaker Continues

Anthem

Cigna

CVS Health

Humana

UnitedHealth Group

Shares of managed-care companies were falling, but analysts say a Democratic win in the Georgia races could mean better funding for health care, and a beefing up of the Affordable Care Act.

Democratic Control of the Senate Is Actually Good for Health Insurance Stocks, Analysts Say

Magellan Health

Centene (CNC) to acquire Magellan Health for providing better healthcare to the most susceptible and underserved communities.

Centene (CNC) to Buy Magellan Health for Better Medical Care

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Magellan Health, Inc. (NASDAQ: MGLN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Centene Corporation (NYSE: CNC).

MAGELLAN HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MGLN and Encourages Investors to Contact the Firm

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Magellan Health, Inc. (NASDAQ: MGLN) and its board of directors concerning the proposed acquisition of the company by Centene Corporation (NYSE: CNC). Stockholders will receive...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Magellan Health, Inc.

Centene Corp. (NYSE: CNC) announced Monday that it has reached a definitive agreement to acquire Magellan Health Inc.

What Centene Gets for Its $2.2 Billion Magellan Acquisition

Health insurer Centene is opening its pocketbook yet again, this time with a $2.2 billion acquisition of Magellan Health, which owns a pharmacy-benefit manager and provides behavioral health services, among other businesses.

Centene Is Climbing on Its Plans to Buy Magellan Health for $2.2 Billion

Magellan Health climbs after agreeing to Centene buyout offer

ST. LOUIS and PHOENIX, Jan. 4, 2021 /PRNewswire/ -- Centene Corporation (NYSE: CNC) and Magellan Health, Inc. (NASDAQ: MGLN) today announced that they have entered into a definitive merger agreement under which Centene will acquire Magellan Health for $95 per share in cash for a total...

Centene Signs Definitive Agreement to Acquire Magellan Health

ST. LOUIS, Dec. 31, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will present at the virtual 39th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2021. Centene will participate in a virtual format on Monday, January 11th at 9:10 a.m. Eastern...

Centene To Present At Virtual JP Morgan 39th Healthcare Conference

Centene has completed the acquisition of PANTHERx, a specialty pharmacy the company the health insurer plans to use in one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases.

Centene Adds Speciality Pharmacy To Health Plan Portfolio

ST. LOUIS, Dec. 30, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that it has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases. "We are...

Centene Completes Acquisition of PANTHERx Rare Pharmacy (PANTHERx)

Centene (CNC) provides an impressive 2021 guidance for key metrics owing to its strong inorganic growth story and a healthy revenue stream.

Centene (CNC) Announces Solid Financial Guidance for 2021

Shares of Centene Corp. fell 1.3% in premarket trading Friday, after the provider of government-sponsored and commercial health care programs provided downbeat profit guidance for next year, but an in-line revenue outlook. The company said it expects 2021 adjusted earnings per share to rise to $5.00 to $5.30, which is below the FactSet consensus of $5.43, from $4.90 to $5.06 this year; the 2020 FactSet consensus is $4.99.

Centene stock falls after downbeat profit outlook for next year

ST. LOUIS, Dec. 18, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its 2021 financial guidance. Total revenues are expected to be $114.1 billion to $116.1 billion, and diluted earnings per share are expected to be $3.82 to $4.06. Adjusted diluted earnings per share...

Centene Corporation Announces 2021 Guidance

Adaptive Biotechnologies

BridgeBio Pharma Inc

Boston Scientific

Thermo Fisher Scientific

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Centene Corp. (NYSE:CNC), BridgeBio Pharma Inc. (NASDAQ:BBIO), Boston Scientific Corp. (NYSE:BSX) and Thermo Fisher Scientific Inc. (NYSE:TMO). This week, Halvorsen revealed a slight reduction to his Adaptive Biotechnologies position according to GuruFocus Real-Time Picks, which is also a Premium feature.

Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter

Centene Corp. (NYSE:CNC) is a health insurance company that specializes in government-sponsored health care programs. In addition to Medicaid and Medicare products, it offers commercial programs and Marketplace operations.

Centene: A Modestly Undervalued Growth Stock

Centene (CNC) to buy specialty pharmacy PANTHERx Rare to penetrate the specialty drug market and cater to patients with complex situations.

Centene (CNC) to Purchase Specialty Pharmacy PANTHERx Rare

ST. LOUIS, Dec. 15, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The...

News for Centene Stock (CNC)